07 October 2020
Nearly 30,000 volunteers will take part in post-registration trials of the coronavirus vaccine developed by Russia’s Vector State Research Center of Virology and Biotechnology, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.
“After the vaccine’s registration the centers of carrying out post-registration trials will be selected, and 30,000 volunteers will take part in them,” the statement said.
The vaccine’s registration procedure is due to be over by October 15.
Medical institutions will receive the vaccine once its mass production is launched.
Earlier, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told that the post-registration trials of the vaccine would begin in November-December 2020 after the first series of the medication are received.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024